Vicero Bio
Preclinical-stage biopharmaceutical company developing modular VHH (single-domain antibody) multivalent therapeutics engineered to enable multi-target immuno-oncology combinations and multi-payload antibody-drug conjugates with improved safety, tumor penetration, and subcutaneous dosing.
Industries
N/A
Products
Lead bispecific PD-1 + CTLA-4 VHH therapeutic (preclinical candidate)
Preclinical multivalent single-domain antibody candidate designed to neutralize PD-1 and CTLA-4 on a single scaffold, showing robust preclinical efficacy and reduced immune-related toxicity in animal models.
Dual/multi-payload ADC candidates (preclinical)
Preclinical antibody-drug conjugate candidates using compact multivalent scaffolds to enable dual or multiple payload delivery for improved tumor targeting and payload efficacy.
Lead bispecific PD-1 + CTLA-4 VHH therapeutic (preclinical candidate)
Preclinical multivalent single-domain antibody candidate designed to neutralize PD-1 and CTLA-4 on a single scaffold, showing robust preclinical efficacy and reduced immune-related toxicity in animal models.
Dual/multi-payload ADC candidates (preclinical)
Preclinical antibody-drug conjugate candidates using compact multivalent scaffolds to enable dual or multiple payload delivery for improved tumor targeting and payload efficacy.
Services
R&D collaborations and co-development
Collaborative partnerships for discovery, target evaluation, and co-development of multispecific IO and ADC programs.
R&D collaborations and co-development
Collaborative partnerships for discovery, target evaluation, and co-development of multispecific IO and ADC programs.
Expertise Areas
- Multispecific antibody engineering
- VHH / single-domain antibody therapeutics
- Antibody-drug conjugate (ADC) development
- Preclinical pharmacology and toxicology
Key Technologies
- VHH (single-domain antibody) engineering
- Multispecific / bispecific antibody design
- Antibody-drug conjugation
- In vivo tumor models and pharmacology